<DOC>
	<DOCNO>NCT00614705</DOCNO>
	<brief_summary>This proof-of-concept study determine PH-797804 reduces neuropathic pain associate post-herpetic neuralgia . Suitable patient randomize receive either PH-797804 placebo 4 week , time also record pain symptom use various pain scale .</brief_summary>
	<brief_title>PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Male female , least 18 year age Patients must pain present 3 month heal Herpes zoster skin rash . There upper limit duration PHN . Patients screen visit ( V1 ) must score ≥40 mm Pain Visual Analog Score ( VAS ) . Patients severe pain , may impair selfassessment pain due postherpetic neuralgia History within previous year : myocardial infarction , cardiac arrhythmia ( e.g . atrial fibrillation , paroxysmal atrial fibrillation , atrial flutter , supraventricular tachycardia , ventricular tachycardia ) , leave ventricular failure , New York Heart Association ( NYHA ) Class IIIIV congestive heart failure require treatment , unstable angina , coronary angioplasty , coronary artery bypass grafting ( CABG ) cerebrovascular accident ( include transient ischemic attack ) . Tuberculosis without treatment and/or positive tuberculin reaction PPD ( Purified Protein Derivative ) without know ( document ) vaccination bacillus CalmetteGuerin vaccine ( BCG ) . A positive approve immunoassay/ELISA blood test TB ( e.g . TB TSPOT™ , QuantiFERONGold Any clinically significant skin lesion describe Common Terminology Criteria Adverse Events Dermatology ( CTCAE ) Version 3.0 ECG abnormality screen randomization Evidence organ dysfunction hematopoietic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>